Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have missed a full four weeks of Mounjaro doses, or are planning to stop temporarily, the short answer is this: the medicine's appetite-suppressing effects will have faded significantly by week four, and most people notice hunger returning and weight beginning to creep back before that point. Mounjaro (tirzepatide) is a prescription-only medicine, and any decision about pausing or stopping should involve the prescriber who manages your treatment. The guide below draws on what clinical evidence and the NHS's tirzepatide medicines guidance tell us about what to expect.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works by activating two gut-hormone receptors, GIP and GLP-1, that together slow how quickly the stomach empties and signal fullness to the brain. Once you stop injecting, the medicine clears from your system over roughly two to three weeks. With a half-life of around five days, levels are meaningfully lower within ten days and largely gone by three weeks. Four weeks off Mounjaro means that pharmacological appetite suppression is essentially absent.
That matters because the reduced hunger you felt on treatment was not simply willpower, it was a measurable biological effect. When that effect lifts, the hormonal signals that drive appetite (ghrelin, in particular) return to baseline or sometimes above it. People often describe this as hunger feeling more urgent or harder to manage than before they started treatment, particularly in the first few weeks after stopping. This is not unusual, and it is not a sign that anything has gone wrong. It is the body's expected response to losing the medicine's influence.
The NHS tirzepatide page notes that stopping the medicine without a plan for ongoing weight management is likely to lead to weight regain, which is consistent with what was observed in SURMOUNT-1 extension data. A question our prescribers hear most weeks is whether the weight will all come back straight away, the honest answer is that it depends on how much lifestyle groundwork was built during treatment, but some regain within a month of stopping is common for most people.
There is no single number that applies to everyone, and it would be misleading to suggest otherwise. What clinical data and the broader SURMOUNT-1 trial tell us is that weight regain after stopping tirzepatide is real and tends to accelerate in the weeks immediately after the medicine clears. The degree varies depending on calorie intake, activity level, how long you were on treatment, and individual metabolic factors.
A four-week pause is shorter than the gaps studied in withdrawal extensions, so the regain in that period is usually less dramatic than a permanent stop. That said, if the gap coincides with a period of disrupted routine, travel, illness or stress, the regain can be faster because those are exactly the circumstances that make it harder to maintain a calorie deficit without the medicine's help. Some people lose very little in a four-week gap; others regain several kilograms. Both outcomes are consistent with the published evidence.
It is also worth knowing that a break does not erase the progress made on treatment. The metabolic improvements, the habits built, the weight already lost, those do not disappear in four weeks. Regain in the gap is a setback, not a reset to zero.
This is where the conversation with your prescriber becomes essential. UK clinical guidance is clear that after a significant gap (and four weeks is significant), tolerance to the medicine should be assumed to have reduced. Restarting at the dose you were taking before the break carries a higher risk of pronounced nausea, vomiting and gastrointestinal discomfort because your system is, in effect, encountering the medicine again as if for the first time.
Most prescribers will recommend stepping back to a lower dose and re-titrating, though the exact starting point depends on how long you had been on treatment, how well you tolerated each previous step, and what dose you were on when you paused. For many people restarting after a gap, beginning again at the 2mg tirzepatide dose is where a prescriber will suggest picking things back up. This is a clinical judgement, not a fixed rule, which is precisely why restarting without a prescriber review is not advisable.
If you are considering Mounjaro treatment for the first time, or are coming to a regulated online service as a transfer patient, the process at a reputable pharmacy includes clinical review before any supply is made. Our clinical team, led by GPhC-registered Independent Prescribers, reviews every restart or transfer case on the same day, you can read more about the team's approach on the clinical lead profile page.
Missed doses happen, a prescription lapse, supply disruption, illness, travel without a cool bag. If four weeks have passed without a dose and the gap was not something you planned with your prescriber, the first step is to let them know before attempting to restart. Do not simply pick up where you left off.
A few practical things are worth checking before your prescriber conversation. First, is your BMI and weight still in the range where treatment is clinically appropriate? Weight may have shifted during the gap. Second, has anything changed medically, a new medicine, a pregnancy test, a surgery coming up? Any of those can affect whether and how treatment should restart. Third, if you sourced your treatment from a regulated UK pharmacy and the gap was caused by a supply or prescription issue, contacting that pharmacy directly is the quickest route to a clinical review. If you are weighing up the costs involved in continuing treatment, that page sets out what a transparent private price typically covers.
A four-week break is manageable. With a clear plan and prescriber support, most people are able to restart treatment, re-titrate without significant difficulty and resume progress. The worst outcome is usually restarting at the wrong dose without any clinical oversight, not the gap itself. For those who were on treatment and are curious about what a supported restart looks like month to month, our guides covering what to expect at two weeks on Mounjaro and what changes by the third week on Mounjaro are useful points of reference for anyone re-entering the early stages of treatment, alongside the four-week-on guide which covers what to expect early in treatment.
If you are ready to discuss restarting or beginning treatment for the first time, start your free consultation and a prescriber will review your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.